English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background and Aim  The accuracy for predicting virological outcomes of peginterferon‐α and ribavirin therapy in patients with chronic hepatitis  C  is limited to approximately 80%, even with   IL 28 B   genotyping. Our  in vitro  study revealed that the numbers of ( TA ) dinucleotide repeats [( TA )n] of rs72258881, which is located in the promoter region of   IL 28 B   gene, might regulate   IL 28 B   transcription. We aimed to evaluate the usefulness of these host factors for predicting virological outcomes of this therapy in response‐guided clinical settings.    Methods  A nationwide, multi‐center prospective study in  J apan determined   IL 28 B   (rs8099917) genotype, ( TA )n of rs72258881, and amino acid substitutions of hepatitis  C  virus and used these for multivariate analysis together with other parameters at pretreatment.    Results  After enrolling 215 patients with genotype 1 and high viral load from 23 hospitals between  O ctober 2009 and  F ebruary 2011, intent‐to‐treat analysis identified 202 patients in whom the final virological outcomes could be determined. Non‐virological response by non‐ TT  genotype was predicted with 79.7% accuracy. When combined with the ( TA )n, the incidences of virological response tended to be higher in the longer ( TA )n group, regardless of rs8099917 genotype. Multivariate logistic regression analysis revealed that rs8099917 non‐ TT  genotype ( P  < 0.001), shorter ( TA )n ( P  = 0.011), mutation of amino acid 70 in the virus core region ( P  = 0.029), and lower levels of serum albumin ( P  = 0.036) were independently associated with non‐virological response.    Conclusions    IL 28 B   genotype and ( TA )n of rs72258881 may independently affect virological outcomes of peginterferon‐α and ribavirin as host factors, even in response‐guided therapy.

Pretreatment prediction of the outcome of response‐guided peginterferon‐α and ribavirin therapy for chronic hepatitis C